August 2016 in “Journal of Investigative Dermatology” Different levels of microRNAs in different parts of the scalp can cause male pattern baldness.
July 2016 in “Cancer Research” Male pattern baldness is linked to a higher risk of certain skin cancers, especially on the scalp.
April 2016 in “Journal of Investigative Dermatology” Male pattern baldness is linked to a higher risk of certain skin cancers, especially on the scalp.
November 2015 in “Hair transplant forum international” PRP may help with hair regrowth in male pattern baldness, but more research is needed.
Plan hair-restoration surgery early for better results in male pattern baldness.
August 2013 in “Hospital Pharmacy” Certain medications can cause serious side effects, including skin reactions, stroke, muscle disorders, tongue swelling, hair loss in women, and liver failure.
Botulinum toxin injections can reduce hair loss and stimulate new hair growth in some men with male pattern baldness.
April 2012 in “The Journal of Urology” Male pattern baldness may predict prostate cancer risk.
Targeting a specific lipid could help treat male pattern baldness.
March 2012 in “Dermatology Times E-News” Men with pattern baldness may have a higher risk of prostate issues.
January 2012 in “Chinese Journal of Aesthetic Medicine” Increased androgen receptor expression in certain hair follicle areas may cause male pattern baldness.
September 2011 in “Hair transplant forum international” Hair transplants can be effective for early male pattern baldness.
Most American men experience hair loss by age 50, with limited effective treatments available and new options not expected soon.
January 2009 in “Revista de Ciências Médicas” Male pattern baldness is a genetic condition causing hair loss, with limited but improving treatment options.
January 2007 in “Annals of The Royal College of Surgeons of England” Removing a hormone-producing adrenal tumor can stop hair loss in women with high testosterone levels.
January 2007 in “Inpharma Weekly” Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.
May 2004 in “Dermatologic Surgery” Most men stopped using finasteride for baldness due to unsatisfactory results or were lost to follow-up, and those who continued saw minimal to moderate improvement.
May 2002 in “Dermatologic Surgery” The method improves natural appearance in hair restoration by properly evaluating and treating the temporal peak region.
January 2001 in “Chinese Journal of Medical Aesthetics and Cosmetology” Micrografts can grow natural hair and most patients are satisfied, but some need multiple procedures.
Surgical treatments like hair transplants can help with male pattern baldness.
January 2024 in “Springer eBooks” Modern hair restoration techniques offer natural results with minimal complications.
April 2020 in “Journal of the Endocrine Society” Male pattern baldness may indicate arterial stiffness in transgender men on long-term testosterone therapy.
February 2023 in “Cureus” Male pattern baldness in medical students is linked to higher depression, loneliness, and internet addiction.
August 2021 in “Journal of The American Academy of Dermatology” Finasteride treatment changes hormone levels in male pattern baldness patients.
April 2021 in “Texila international journal of academic research” Both topical and oral finasteride are equally effective for treating male pattern baldness.
June 2017 in “IP Indian journal of clinical and experimental dermatology” Using 10% topical minoxidil, oral finasteride, and microneedling together can effectively treat Male Pattern Baldness with high patient satisfaction and no major side effects.
20 citations,
September 1987 in “The Lancet” November 2023 in “Plastic and Reconstructive Surgery – Global Open” Americans see hair transplants as valuable for treating hair loss and want them to be more affordable and tailored to each gender.
March 2020 in “Zenodo (CERN European Organization for Nuclear Research)”